MediPal Holdings Corporation Stock Other OTC
Equities
MAHLY
US58502T1079
Pharmaceuticals
Sales 2024 | 3,559B 22.65B | Sales 2025 * | 3,607B 22.95B | Capitalization | 471B 3B |
---|---|---|---|---|---|
Net income 2024 | 41.47B 264M | Net income 2025 * | 34.15B 217M | EV / Sales 2024 | 0.14 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.13 x |
P/E ratio 2024 |
11.8
x | P/E ratio 2025 * |
14.2
x | Employees | - |
Yield 2024 |
2.59% | Yield 2025 * |
2.8% | Free-Float | 84.27% |
Managers | Title | Age | Since |
---|---|---|---|
Shuichi Watanabe
CEO | Chief Executive Officer | 72 | 00-03-31 |
Midori Ito
CMP | Compliance Officer | - | - |
Takeshi Yanagida
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Shuichi Watanabe
CEO | Chief Executive Officer | 72 | 00-03-31 |
Toshihide Yoda
ADM | Chief Administrative Officer | 61 | 10-05-31 |
Director/Board Member | 69 | 77-03-31 |
1st Jan change | Capi. | |
---|---|---|
+18.63% | 72.89B | |
-6.25% | 23.48B | |
+4.65% | 8.67B | |
+9.32% | 8.51B | |
-25.47% | 7.71B | |
+13.37% | 5.21B | |
+1.58% | 4.23B | |
+5.71% | 4.08B | |
+1.24% | 3.99B |